<DOC>
	<DOCNO>NCT00465673</DOCNO>
	<brief_summary>Primary objective : To determine brain response rate Lipo-Dox breast cancer patient brain metastasis Secondary objective : 1 . To determine overall objective response rate ( ORR ) 2 . To determine progression free survival , duration objective response 3 . To evaluate overall survival ( OS ) 4 . To assess safety profile</brief_summary>
	<brief_title>Liposomal Doxorubicin ( Lipo-Dox ) Patients With Brain Metastasis From Breast Cancer</brief_title>
	<detailed_description>This open-label , non-comparative phase II clinical trial . Approximately thirty-three patient enrol order obtain twenty-nine evaluable subject receive two cycle study treatment Simon 's 2-stage optimal design . Duration subject involvement : Study treatment administer disease progression , intolerable toxicity , consent withdrawal . Recruitment period : 10 month</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Histologically cytologically prove breast cancer Relapse/recurrent brain metastasis progression brain radiotherapy Presence brain measurable disease define least one brain lesion measure least 1 dimension ³ 20 mm magnetic resonance image ( MRI ) Prior chemotherapy hormone therapy metastatic breast cancer allow Performance status ECOG 0 , 1 , 2 With normal leave ventricular ejection fraction normal ventricular contractility Age 21 year old Life expectancy equal longer 3 month Ability understand willingness sign write informed consent document Prior anthracyclinecontaining chemotherapy cumulative dose exceed 400mg/m2 doxorubicin 750 mg/m2 Epirubicin Surgery , radiotherapy , hormonal therapy chemotherapy within 4 week prior enter study Prior liposomal doxorubicin treatment Concurrent chemotherapy , radiotherapy , hormonal therapy , investigational drug except nondisease relate condition ( e.g . insulin diabetes ) study period Other malignancy exception curative treat nonmelanoma skin cancer cervical carcinoma situ within 5 year prior enter study Brain metastasis define meninges metastasis Presence serious concomitant illness might aggravate study medication : Uncontrolled infection ( active serious infection control antibiotic ) Active cardiac disease e.g . decompensate myocardial infarction within 6month period precede entry study . History ventricular arrhythmia congestive heart failure . Presence abnormal leave ventricular ejection fraction Hematopoietic function define : Hemoglobin＜10g/dl ANC＜ 1,500/uL Platelets＜100,000/uL Organ function define : Total bilirubin ＞1.5 × ULN ALT / AST＞3 × ULN ( ＞5.0 x ULN hepatic metastasis ) Creatinine ＞1.5 × ULN Mental status fit clinical trial Pregnant breast feed woman , woman childbearing potential unless use reliable appropriate contraceptive method</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>brain metastatsis</keyword>
	<keyword>Lipo-Dox</keyword>
</DOC>